Astria Therapeutics (NASDAQ:ATXS) Stock Price Down 5.3% – Here’s What Happened

Astria Therapeutics, Inc. (NASDAQ:ATXS)’s share price fell 5.3% during trading on Friday . The company traded as low as $9.55 and last traded at $9.56. 41,906 shares changed hands during mid-day trading, a decline of 93% from the average session volume of 612,849 shares. The stock had previously closed at $10.09.

Analyst Ratings Changes

Several brokerages have recently weighed in on ATXS. Wedbush reiterated an “outperform” rating and issued a $22.00 price target on shares of Astria Therapeutics in a research report on Tuesday, August 13th. HC Wainwright reaffirmed a “buy” rating and set a $16.00 target price on shares of Astria Therapeutics in a report on Thursday. Oppenheimer increased their price target on shares of Astria Therapeutics from $26.00 to $28.00 and gave the stock an “outperform” rating in a report on Thursday. TD Cowen started coverage on shares of Astria Therapeutics in a research note on Monday, July 29th. They set a “buy” rating and a $35.00 price objective for the company. Finally, Evercore ISI upgraded shares of Astria Therapeutics to a “strong-buy” rating in a research note on Wednesday, August 14th. Five research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $25.60.

Astria Therapeutics Price Performance

The company has a fifty day moving average price of $11.40 and a 200 day moving average price of $10.62. The company has a market cap of $528.66 million, a PE ratio of -4.48 and a beta of 0.71.

Hedge Funds Weigh In On Astria Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of ATXS. FMR LLC raised its position in shares of Astria Therapeutics by 29.2% during the 3rd quarter. FMR LLC now owns 7,822,275 shares of the biotechnology company’s stock valued at $86,123,000 after buying an additional 1,767,714 shares in the last quarter. RA Capital Management L.P. raised its position in Astria Therapeutics by 1.2% during the third quarter. RA Capital Management L.P. now owns 5,105,213 shares of the biotechnology company’s stock valued at $56,208,000 after purchasing an additional 61,457 shares in the last quarter. Vestal Point Capital LP raised its position in Astria Therapeutics by 23.1% during the third quarter. Vestal Point Capital LP now owns 4,000,000 shares of the biotechnology company’s stock valued at $44,040,000 after purchasing an additional 750,000 shares in the last quarter. Vanguard Group Inc. boosted its holdings in shares of Astria Therapeutics by 23.4% in the 1st quarter. Vanguard Group Inc. now owns 2,535,891 shares of the biotechnology company’s stock worth $35,693,000 after purchasing an additional 480,184 shares in the last quarter. Finally, Millennium Management LLC increased its position in shares of Astria Therapeutics by 13.5% during the 2nd quarter. Millennium Management LLC now owns 1,842,063 shares of the biotechnology company’s stock valued at $16,763,000 after purchasing an additional 218,518 shares during the last quarter. Hedge funds and other institutional investors own 98.98% of the company’s stock.

About Astria Therapeutics

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.